TOP NEWS: GlaxoSmithKline And Clover Team Up On Coronavirus Vaccine

(Alliance News) - GlaxoSmithKline PLC and Chinese firm Clover Biopharmaceuticals are to ...

Alliance News 24 February, 2020 | 9:30AM
Email Form

(Alliance News) - GlaxoSmithKline PLC and Chinese firm Clover Biopharmaceuticals are to collaborate on a coronavirus vaccine candidate, the two partners announced on Monday.

Clover has entered a research collaboration deal with Glaxo concerning Clover's "protein-based coronavirus vaccine candidate" known as COVID-19 S-Trimer.

Under the deal, Clover said, Glaxo will provide its "pandemic adjuvant system" to Clover to evaluate S-Trimer in preclinical studies. Clover described Glaxo as "a leader in the development of innovative vaccines using different adjuvant systems".

When making a vaccine, an adjuvant can be added to cause an enhanced immune response. In this way, an adjuvant helps provide immunity that is stronger and last for longer compared to just the vaccine alone.

Thomas Breuer, chief medical officer of GSK Vaccines, said: "We are proud to contribute to cutting edge research from scientists at Clover Biopharmaceuticals in China as part of our strategy to make our adjuvant technology available to selected partners who have a promising vaccine candidate against the newly emerged coronavirus."

Breuer added: "The use of an adjuvant is of particular importance in a pandemic situation since it may reduce the amount of vaccine protein required per dose, allowing more vaccine doses to be produced and therefore contributing to protect more people."

Shares in Glaxo were down 1.9% at 1,626.00 pence in London on Monday morning.

By Anna Farley;

Copyright 2020 Alliance News Limited. All Rights Reserved.

Email Form

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
GlaxoSmithKline PLC 1,525.60 GBX 0.32

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

Audience Confirmation

By clicking 'accept' I acknowledge that this website uses cookies and other technologies to tailor my experience and understand how I and other visitors use our site. See 'Cookie Consent' for more detail.

  • Other Morningstar Websites
© Copyright 2020 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Cookies